PARP-1靶向俄歇发射体体外高LET细胞毒性但实体瘤模型疗效有限
研究评估PARP-1靶向俄歇发射体125I-KX1在神经母细胞瘤临床前模型中的细胞毒性与疗效。125I-KX1在19种细胞系中高细胞毒性并直接导致DNA双链断裂,亚细胞剂量学显示其效力约为131I-KX1的两倍,但体内疗效仍低于α发射体211At-MM4且需更高活度。
要点
- 125I-KX1在19种神经母细胞瘤细胞系中显示高细胞毒性并直接引起DNA双链断裂。
- 基于亚细胞剂量学,125I-KX1效力约为131I-KX1的两倍,而胞质125I-MIBG生物效应低。
- 体内肿瘤微剂量学显示125I-KX1疗效低于211At-MM4且需显著更高活度。
核心结论
- 染色质靶向俄歇治疗对高风险神经母细胞瘤细胞具有致死性,并可能用于微转移病变。
- 本研究首次提供PARP-1靶向俄歇发射体导致细胞致死的证据,呼吁进一步研究靶向俄歇治疗。
研究设计与样本
- 临床前研究,使用放射性标记的PARP抑制剂125I-KX1将俄歇辐射递送至PARP-1。
- 体外细胞毒性在19种神经母细胞瘤细胞系中评估,并在敏感与耐药细胞系对中进行深入药理学分析。
- 采用免疫荧光显微镜表征125I-KX1诱导的DNA损伤,并基于实验药理学变量建模体外与体内微剂量学。
主要发现
- 125I-KX1在多种神经母细胞瘤细胞系中体外高度细胞毒性,直接导致DNA双链断裂。
- 基于亚细胞剂量学,125I-KX1效力约为131I-KX1的两倍,而胞质125I-间碘苄胍显示低生物效应。
- 尽管能将聚焦辐射剂量递送至细胞核,125I-KX1仍不如其α发射体类似物211At-MM4有效。
- 基于肿瘤微剂量学,125I-KX1达到等效体内疗效需要显著更高的活度。
临床怎么用
- 染色质靶向俄歇治疗对高风险神经母细胞瘤细胞有致死潜力,可能适用于微转移病变。
- 当前体内实体瘤模型中125I-KX1疗效有限且需更高活度,尚不支持替代α发射体或现有疗法。
局限性
- 研究为临床前模型,结论需进一步体内外研究验证。
- 125I-KX1在实体瘤模型中体内疗效有限,需显著更高活度才能达到与211At-MM4等效的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The currently available therapeutic radiopharmaceutical for high-risk neuroblastoma, 131I-metaiodobenzylguanidine, is ineffective at targeting micrometastases because of the low-linear-energy-transfer (LET) properties of high-energy β-particles. In contrast, Auger radiation has high-LET properties with nanometer ranges in tissue, efficiently causing DNA damage when emitted near DNA. The aim of this study was to evaluate the cytotoxicity of targeted Auger therapy in preclinical models of high-risk neuroblastoma. Methods: We used a radiolabled poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor called 125I-KX1 to deliver Auger radiation to PARP-1, a chromatin-binding enzyme overexpressed in neuroblastoma. The in vitro cytotoxicity of 125I-KX1 was assessed in 19 neuroblastoma cell lines, followed by in-depth pharmacologic analysis in a sensitive and resistant pair of cell lines. Immunofluorescence microscopy was used to characterize 125I-KX1-induced DNA damage. Finally, in vitro and in vivo microdosimetry was modeled from experimentally derived pharmacologic variables. Results:125I-KX1 was highly cytotoxic in vitro across a panel of neuroblastoma cell lines, directly causing double-strand DNA breaks. On the basis of subcellular dosimetry, 125I-KX1 was approximately twice as effective as 131I-KX1, whereas cytoplasmic 125I-metaiodobenzylguanidine demonstrated low biological effectiveness. Despite the ability to deliver a focused radiation dose to the cell nuclei, 125I-KX1 remained less effective than its α-emitting analog 211At-MM4 and required significantly higher activity for equivalent in vivo efficacy based on tumor microdosimetry. Conclusion: Chromatin-targeted Auger therapy is lethal to high-risk neuroblastoma cells and has the potential to be used in micrometastatic disease. This study provides the first evidence for cellular lethality from a PARP-1-targeted Auger emitter, calling for further investigation into targeted Auger therapy.
引用
- Lee H, Riad A, Martorano P, et al. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. J Nucl Med. 2019. PMID: 31676730. doi:10.2967/jnumed.119.233965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。